Benefits and risks of oral contraception

2010 ◽  
pp. 2191-2195
Author(s):  
John Guillebaud
Keyword(s):  
Colorectal Cancer ◽  
Oral Contraceptive ◽  
Menstrual Cycle ◽  
Oral Contraceptives ◽  
Oral Contraception ◽  
Combined Oral Contraceptives

Efficacy of the ‘pill’ as an oral contraceptive—users of combined oral contraceptives (COC) must understand the importance of not lengthening the pill-free (contraception-deficient) time, and be appropriately advised if prescribed enzyme-inducing drugs. Noncontraceptive benefits of COC use—these include fewer disorders of the menstrual cycle and less risk of colorectal cancer and cancers of the ovary and endometrium, which may sometimes provide the principal indication for prescription....

Urine Free Dopamine in Normal Primigravid Pregnancy and Women Taking Oral Contraceptives

1981 ◽  
Vol 61 (4) ◽  
pp. 423-428 ◽  
Author(s):  
C. M. Perkins ◽  
K. W. Hancock ◽  
G. F. Cope ◽  
M. R. Lee
Keyword(s):  
Oral Contraceptive ◽  
Menstrual Cycle ◽  
Oral Contraceptives ◽  
Normal Volunteer ◽  
Combined Oral Contraceptives ◽  
Combined Oral Contraceptive ◽  
Normal Menstrual Cycle

1. Urine free dopamine was estimated at predetermined points of the menstrual cycle in normal volunteer subjects and in women taking a combined oral contraceptive. 2. There was no alteration in 24 h urine dopamine during the normal menstrual cycle but, in contrast, combined oral contraceptives produced a fall which recovered premenstrually. 3. In 19 primigravid subjects 24 h urine free dopamine was estimated at monthly intervals throughout pregnancy and at the time of the postnatal examination. 4. Urine dopamine was elevated throughout pregnancy when compared with postnatal values. Women receiving an oral progestogen contraceptive at the time of the postnatal examination showed a further fall in urine dopamine.

Urinary melatonin, LH, oestradiol, progesterone excretion during the menstrual cycle or in women taking oral contraceptives

1987 ◽  
Vol 116 (1) ◽  
pp. 145-149 ◽  
Author(s):  
Jocelyne Brun ◽  
Bruno Claustrat ◽  
Michel David
Keyword(s):  
Oral Contraceptive ◽  
Menstrual Cycle ◽  
Urinary Excretion ◽  
Oral Contraceptives ◽  
Coefficient Of Variation ◽  
Luteal Phase ◽  
Positive Relationship ◽  
Follicular Phase ◽  
The Other ◽  
Normal Women

Abstract. Nocturnal urinary excretion of melatonin, LH, progesterone and oestradiol was measured by radioimmunoassay in nine normal women during a complete cycle. In addition, these hormonal excretions were studied in two women taking an oral contraceptive. A high within-subject coefficient of variation was observed for melatonin excretion in the two groups. In the nine normal cycling women, melatonin excretion was not decreased at the time of ovulation, but was significantly increased during the luteal phase compared with that of the follicular phase (P < 0.01). These data are consistent with a positive relationship between melatonin and progesterone during the luteal phase. In the two women under an oral contraceptive, melatonin excretion was found within the same range as for the other nine. The results are discussed in terms of pineal investigation in human.

scholarly journals Combined oral contraception and treatment of new coronavirus infection (COVID-19): drug interaction issues

2021 ◽  
pp. 30-39
Author(s):  
O. A. Limanova ◽  
O. A. Gromova ◽  
L. E. Fedotova
Keyword(s):  
Drug Interaction ◽  
Oral Contraceptives ◽  
Female Body ◽  
Oral Contraception ◽  
Combined Oral Contraceptives ◽  
Coronavirus Infection

Combined oral contraception and treatment of new coronavirus infection (COVID-19): issues of drug interaction This article examines the interaction of combined oral contraceptives with drugs recommended in the treatment of new coronavirus infection (COVID-19) at the pharmacodynamic and pharmacokinetic levels, with an assessment of the effectiveness and safety of therapy for the female body.

Starting oral contraceptives – which, when and how?

1992 ◽  
Vol 30 (11) ◽  
pp. 41-44
Keyword(s):  
Oral Contraceptive ◽  
Sexual Activity ◽  
Medical History ◽  
Oral Contraceptives ◽  
New Products ◽  
Oral Contraceptive Pill ◽  
Oral Contraception ◽  
Planned Parenthood ◽  
Combined Oral Contraceptive ◽  
Free Interval

About one quarter of women in Britain aged 18–44 use oral contraceptives,1 and almost half of those aged 20–29.2 Many will use more than one type during their years of sexual activity. Changes will occur as new products are introduced and new risks identified or in response to unwanted effects. Decisions may also be prompted by the need to restart oral contraception after a break as part of planned parenthood. Oral contraception is chosen chiefly because it is reliable and does not interrupt spontaneous sexual activity. Whether a combined oral contraceptive pill (COC) or a progestagen-only pill (POP) would be the more appropriate depends mainly on the woman’s medical history, smoking habits and age. Most women will want good cycle control, and a few will prefer to take an inactive pill for a few days in each cycle rather than have a pill-free interval. This article discusses the choice when starting, restarting or switching oral contraception.

Does the Use of Oral Contraception Depress DZ Twinning Rates?

1987 ◽  
Vol 36 (3) ◽  
pp. 409-415 ◽  
Author(s):  
D. Campbell ◽  
B. Thompson ◽  
C. Pritchard ◽  
M. Samphier
Keyword(s):  
Oral Contraceptive ◽  
Oral Contraceptives ◽  
Early Pregnancy ◽  
Contraceptive Use ◽  
Oral Contraception ◽  
Secular Trends ◽  
Control Groups ◽  
Blood Samples ◽  
Oral Contraceptive Use

AbstractData based on total births from a geographically defined population with zygosity determined from blood samples and placentation and with data on the use of oral contraceptives routinely collected in early pregnancy showed no association between oral contraceptive use prior to pregnancy in either MZ or DZ twinning. Three mutually exclusive control groups of singletons were used to take account of age, parity and secular trends.

▾Mercilon - a new low-dose combined oral contraceptive

1989 ◽  
Vol 27 (13) ◽  
pp. 51-52
Keyword(s):  
Oral Contraceptive ◽  
Oral Contraceptives ◽  
Low Dose ◽  
Combined Oral Contraceptives ◽  
Younger Women ◽  
Combined Oral Contraceptive

Mercilon (Organon) is a new combined oral contraceptive “developed with the mature pill user in mind”. Each tablet contains ethinyloestradiol 20µg + desogestrel 150µg. It is a lower dose version of Marvelon (ethinyloestradiol 30µg + desogestrel 150µg),1 which is intended for younger women, and like Marvelon contains the highly selective progestagen desogestrel, which is said to be more progestagenic and less androgenic than other commonly used progestagens.2 Like other monophasic combined oral contraceptives, Mercilon is taken daily for 21 days, followed by a 7-day break.

Idiopathic Thromboembolism Associated with Triphasic Oral Contraceptives

DICP ◽  
1989 ◽  
Vol 23 (10) ◽  
pp. 773-775 ◽  
Author(s):  
Linda J. Miwa ◽  
Ann L. Edmunds ◽  
Mark S. Shaefer ◽  
Stephen C. Raynor
Keyword(s):  
Oral Contraceptive ◽  
Menstrual Cycle ◽  
Adverse Effects ◽  
Oral Contraceptives ◽  
Thrombotic Event ◽  
Thromboembolic Disease ◽  
Contraceptive Methods ◽  
Increased Risk ◽  
Hormonal Fluctuations ◽  
Effective Contraception

Oral contraceptives are one of the most effective and widely used of the reversible contraceptive methods. Thromboembolic disease associated with the use of oral contraceptives has been widely reported. In recent years, attempts to understand the pathogenesis of oral contraceptive-induced thromboembolic disease have found a correlation between larger estrogen doses and increased risk for a thrombotic event. Because the newer triphasic oral contraceptives provide effective contraception with a method of administration that mimics normal hormonal fluctuations during the menstrual cycle, some prescribers may infer that these products are associated with a decreased incidence of adverse effects over alternative oral contraceptives. We present two cases of idiopathic thromboembolism associated with the use of a triphasic oral contraceptive with a discussion of the proposed pathogenic mechanisms for these events.

Sign in / Sign up

Export Citation Format

Share Document